Skip to main navigation Skip to search Skip to main content

Corrigendum: Integrated metabolomics and proteomics reveal biomarkers associated with hemodialysis in end-stage kidney disease(Front. Pharmacol., (2023), 14, (1243505), 10.3389/fphar.2023.1243505)

  • Weiwei Lin
  • , Fatemeh Mousavi
  • , Benjamin C. Blum
  • , Christian F. Heckendorf
  • , Jarrod Moore
  • , Noah Lampl
  • , Mark McComb
  • , Sergei Kotelnikov
  • , Wenqing Yin
  • , Nabil Rabhi
  • , Matthew D. Layne
  • , Dima Kozakov
  • , Vipul C. Chitalia
  • , Andrew Emili
  • Boston University
  • Stony Brook University
  • VA Medical Center
  • Massachusetts Institute of Technology

Research output: Contribution to journalComment/debate

Abstract

In the published article, there was an error in the Funding statement. The current statement is “This work was supported by operating funds to AE from the Canadian Institutes of Health Research (FDN-148399) and generous start-up funds from Boston University.” The correct Funding statement appears below. “This work was supported by operating funds to AE from the Canadian Institutes of Health Research (FDN-148399) and generous start-up funds from Boston University. This work was also supported by funds to VC from the National Heart Lung and Blood Institute (1R01HL166608).” The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Original languageEnglish
Article number1376058
JournalFrontiers in Pharmacology
Volume15
DOIs
StatePublished - 2024

Keywords

  • ESKD
  • integrated omics
  • metabolomics
  • nLC-MS/MS
  • proteomics

Fingerprint

Dive into the research topics of 'Corrigendum: Integrated metabolomics and proteomics reveal biomarkers associated with hemodialysis in end-stage kidney disease(Front. Pharmacol., (2023), 14, (1243505), 10.3389/fphar.2023.1243505)'. Together they form a unique fingerprint.

Cite this